anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As mass coral bleaching events become more frequent, it is increasingly important to elucidate the factors underlying coral susceptibility and survival. We measured photosynthesis, respiration, and O2 concentration at the coral tissue surface, Symbiodiniaceae genotypes, and energy metabolic enzyme activities in Agaricia agaricites and Orbicella franksi throughout experimentally-induced thermal bleaching (+3 °C). A. agaricites colonies started to bleach two days into the thermal treatment and were fully bleached between Days 19-31. In contrast, O. franksi colonies only started to bleach on Day 12 and five colonies fully bleached between Days 24-38 while the remining three colonies took up 55 days. Both species experienced decreased photosynthesis and respiration rates as bleaching progressed. As a result, daytime O2 concentration at the coral surface shifted from hyperoxia in unbleached corals to normoxia in partially bleached corals, and to near hypoxia in fully bleached corals. Additionally, nighttime tissue surface O2 concentration shifted from hypoxia to normoxia, likely resulting from decreased symbiotic algae density, respiration, and photosynthates that fuel coral aerobic respiration. Genetic profiling of internal transcribed spacer 2 (ITS2) revealed differences in Symbiodiniaceae clade proportions between control and bleached colonies. Activity levels of energy metabolic enzymes did not significantly vary between control and bleached A. agaricites, but malate dehydrogenase and strombine dehydrogenase activities were significantly higher in bleached O. franksi colonies compared to controls. These differences were driven by the three O. franksi colonies that took the longest to bleach and contained >98 % Durusdinium sp. D1. The shifts in O2 dynamics within the microhabitat of bleached corals may have important implications for the metabolism of the coral holobiont while the changes in Symbiodiniaceae ITS2 profile and the upregulation of energy metabolic enzymes identify a potential factor contributing to bleaching dynamics.
Healthy volunteers, defined as having an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73m\^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
The invention discloses a new strain of streptomycete, named streptomycete II-2-2-2, which is preserved in China general microbiological culture Collection center (CGMCC) No.23479 and has a preservation date of 2021, 9 months and 24 days. Streptomyces II-2-2-2 is yellow brown on a solid culture medium of Gao's No. I, is small and round, has no luster of surface folds, has a central bulge, has filamentous cells at the edge, has cream-colored aerial hyphae and dark brown matrix hyphae, has compact texture and dry and firm surface. Under microscopic observation, mycelium diameter was 0.7-0.9 μm, spore diameter was 0.4-0.6 μm, and gram staining was positive. Experiments prove that Streptomyces (Streptomyces sp.) II-2-2-2 has rich natural product production capacity, can be used for antibiotic discovery, and is worthy of further research and analysis on secondary metabolites and biosynthesis gene clusters.
Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
1341121 Medical and like capsules R P SCHERER CORP 19 April 1971 [17 July 1970] 21539/71 Heading A5B [Also in Division B8]  Soft gelatin capsules are produced containing a fill which is in moisture equilibrium with the shell, and which is a macromolecular gel-lattice matrix containing an active ingredient and from 5-20% by weight of water. The fill is encapsulated whilst in the liquid, i.e. molten, state by any of the conventional methods used to fill soft gelatin capsules. In particular, a fill containing 5-58% by weight of water may be used and the final water content reduced to 5-20% by drying the formed capsules. Suitable materials for the gel-lattice matrix are water-soluble polypeptides, e.g. gelatin, casein, collagen, soya protein, albumin and soy peptone, polysaccharides, e.g. pectin, agar, tragacanth, chondrus, alginates, guar, modified starch and Icelandic moss, and synthetic polymers e.g. P.V.P., methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, sodium cellulose sulphate, polyacrylic acid, polyethylene maleic anhydride and polyvinyl alcohol. Numerous examples are given in which the active materials are a variety of pharmaceuticals.
1368667 Producing cephalosporin C A  compounds ELI LILLY & CO 22 Aug 1972 [23 Aug 1971] 39129/72 Heading C2A  Cephalosporin C A  compounds are prepared by reacting a crude cephalosporin C compound with a pyridine in the presence of thiocyanate ions in an aqueous medium at pH 6 to 7-5 for 4 to 6 hours at 55-70 C. Thereafter, a non-oxidizing mineral acid (e.g. HCl) is added to the reaction mixture with stirring to lower the pH to 2À8 to 3À5. Stirring is continued for 15 to 45 minutes, filterable material is separated, more acid is added to pH 1 to 1-5 and the precipitated cephalosporin-C A  hydrothiocyanate salt is collected. The salt may be decomposed, e.g. by treatment with a liquid amine anion exchange resin, and purified by conventional methods, e.g. by scrubbing with chloroform and recrystallization.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes a new compound - 1-hydroxy-2-naphthalenecarboxylate of 4-hydroxy-α′-[[[6-(4-phenylbutoxy)hexyl] amino] methyl]-1,3-benzenedimethanol (salmeterol xinafoate) as easily fluidized crystalline form and exhibiting controlled particle size from 1 to 10 microns and dynamic volume density less 0.1 g x cm -3  that can be used for preparing a pharmaceutical compound with an acceptable carrier. Invention describes also a pharmaceutical composition that can be used for inhalation and containing the above indicated compound. The composition is easy for using and can be fluidized easily. EFFECT: improved quality and properties of the composition. 9 cl, 48 dwg, 6 tbl, 14 ex
The COVID-19 pandemic caused occupational disruption and adverse health outcomes in community-dwelling older adults. This study aimed to investigate the extent of occupational disruption in older adults and its relationship to health-related quality of life (QOL), depression, and frailty. In this cross-sectional study, retention rates in four activity domains and relationships with health outcomes were examined in Japanese older adults aged ≥65 years (n=163) using canonical correlation analysis (CCA) and mixed linear models. More than 25% of activities were restricted compared with the pre-pandemic period. CCA demonstrated correlations between four retention rates and health outcomes (canonical correlation = .42, p = .0003). Retention in instrumental and social activities independently predicted QOL and depression (p < .05). This study highlights that different activities may have different effects on health outcomes and can provide community occupational therapy practitioners with a perspective to assess occupational disruption and identify activities for intervention.
For patients randomized to vericiguat, a starting dose of 2.5mg will be initiated at the randomization visit. At pre-specified titration visits, subjects will be up-titrated to vericiguat 5mg and then to the target dose of vericiguat 10mg using titration criteria based on mean systolic blood pressure and evaluation for clinical symptoms. Vericiguat will be administered in the background of optimal medical therapy for cardiomyopathy/heart failure.
BACKGROUND: UBE2C was reported to play carcinogenic effects in diverse cancers. However, the role of UBE2C in osteosarcoma was poorly understood, and its functional mechanisms were not fully clarified.
METHODS: RT-qPCR was used to assess the expression of UBE2C mRNA and miR-140-3p, and western blot technique was used to examine the UBE2C protein and PI3K/AKT pathway-associated proteins. CCK-8 test was applied to measure cell proliferation, and wound healing assay were used to measure migration. Using animal studies, the function of UBE2C in vivo was evaluated. Dual-luciferase reporter assay was used to confirm the potential interaction among UBE2C and miR-140-3p.
RESULTS: In osteosarcoma cells as well as tumor samples, UBE2C was strongly expressed. Osteosarcoma cell proliferation as well as cell migration were inhibited by UBE2C knockdown, and PI3K/AKT signaling activity was diminished. In addition, UBE2C knockdown impeded tumor growth in animal models. UBE2C expression was lessened by miR-140-3p as miR-140-3p targets it. UBE2C is overexpressed which promote osteosarcoma proliferation as well as migration, and strengthened the PI3K/AKT signaling activity, while forced miR-140-3p expression partially abolished these effects.
CONCLUSION: UBE2C, targeted by miR-140-3p, drove carcinogenic effects in osteosarcoma through activating the PI3K/AKT pathway.
Interaction between extracellular matrix (ECM) components plays an important role in the regulation of cellular behavior and hence in tissue function. Consequently, characterization of new interactions within ECM opens the possibility of studying not only the functional but also the pathological consequences derived from those interactions. We have previously described the interaction between fibulin2 and ADAMTS-12 in vitro and the effects of that interaction using cellular models of cancer. Now, we generate a mouse deficient in both ECM components and evaluate functional consequences of their absence using different cancer and inflammation murine models. The main findings indicate that mice deficient in both fibulin2 and ADAMTS12 markedly increase the development of lung tumors following intraperitoneal urethane injections. Moreover, inflammatory phenotype is exacerbated in the lung after LPS treatment as can be inferred from the accumulation of active immune cells in lung parenchyma. Overall, our results suggest that protective effects in cancer or inflammation shown by fibulin2 and ADAMTS12 as interactive partners in vitro are also shown in a more realistic in vivo context.
Adult Patients: A loss of 5% or more of body weight occurred in 7% of patients treated with venlafaxine hydrochloride extended-release capsules and 2% of placebo-treated patients in the short-term placebo-controlled major depressive disorder trials. The discontinuation rate for weight loss associated with venlafaxine hydrochloride extended-release capsules was 0.1% in major depressive disorder studies. In other placebo-controlled trials, 4% of the patients treated with venlafaxine hydrochloride extended-release capsules and 1% of the placebo-treated patients sustained a loss of 7% or more of body weight during up to 6 months of treatment. None of the patients receiving venlafaxine hydrochloride extended-release capsules in other studies discontinued for weight loss.   
  
The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Co-administration of venlafaxine extended-release tablets and weight loss agents is not recommended. Venlafaxine extended-release tablets are not indicated for weight loss alone or in combination with other products.   
  
Pediatric Patients: Weight loss has been observed in pediatric patients (ages 6 -17) receiving venlafaxine hydrochloride extended-release capsules. In a pooled analysis of four eight-week, double-blind, placebo-controlled, flexible dose outpatient trials for major depressive disorder (MDD) and another disorder, patients treated with venlafaxine hydrochloride extended-release capsules lost an average of 0.45 kg (n=333), while placebo-treated patients gained an average of 0.77 kg (n=333). More patients treated with venlafaxine hydrochloride extended-release capsules than with placebo experienced a weight loss of at least 3.5% in the studies (18% of patients treated with venlafaxine hydrochloride extended-release capsules vs. 3.6% of placebo-treated patients; p<0.001). In a 16-week, double-blind, placebo-controlled, flexible dose outpatient study for another disorder, venlafaxine hydrochloride extended-release capsule-treated patients lost an average of 0.75 kg (n=137), while placebo-treated patients gained an average of 0.76 kg (n=148). More patients treated with venlafaxine hydrochloride extended-release capsules than with placebo experienced a weight loss of at least 3.5% in the study (47% of patients treated with venlafaxine hydrochloride extended-release capsules vs. 14% of placebo-treated patients; p<0.001). Weight loss was not limited to patients with treatment-emergent anorexia [ see Warnings and Precautions ( 5.9)] .   
  
The risks associated with longer-term use of venlafaxine hydrochloride extended-release capsules were assessed in an open-label MDD study of children and adolescents who received venlafaxine hydrochloride extended-release capsules for up to six months. The children and adolescents in the study had increases in weight that were less than expected based on data from age-and sex-matched peers. The difference between observed weight gain and expected weight gain was larger for children (<12 years old) than for adolescents (≥12 years old).
Patient identification is transmitted to a health care provider prior to the patient arriving at the health care provider. The patient identification may be a driver's license, health insurance card, or other identification, and may be used to pre-register the patient. The transmission may include other information, such as health status, purpose of visit, intended procedures, symptoms, or other information. The transmission may be made via a device, such as a cellular telephone, where the information may be encrypted and transmitted using a secure mechanism. The system may be used by ambulance personnel, paramedics, or other emergency responders to notify a hospital, for example, of an inbound patient, as well as by patients prior to an appointment. The system may also be used by clinicians or other health care providers to prepare for emergent or non-emergent patients prior to arrival.
PURPOSE: A cosmetic composition is provided to improve a skin exfoliation effect by affecting a keratin cell which is a skin epidermis outermost layer, have a marked effect on improving skin pigmentation and skin tone, have an excellent moisturizing effect and minimize skin irritation, thereby having no side effects. CONSTITUTION: A cosmetic composition includes a mixture in which gluconolactone and lactobionic acid are mixed in a weight ratio of 1:1.5 to 1:2.0 as an active ingredient. The cosmetic composition is used for skin exfoliating, skin whitening or skin tone improvement. The cosmetic composition includes 0.01-40 weight% of the mixture based on the whole cosmetic composition. The cosmetic composition includes 1-20 weight% of the gluconolactone and 1-40 weight% of the lactobionic acid based on the cosmetic composition. [Reference numerals] (AA) Before use; (BB) After use
BACKGROUND AND PURPOSE: Dislocations continue to be a serious complication after primary total hip arthroplasty (THA). Our primary aim was to report the "true" incidence of dislocations in Denmark and secondarily to validate a previously developed algorithm designed to identify THA dislocations in the updated version of the Danish National Patient Register (DNPR), based on data from the Danish Hip Arthroplasty Register (DHR).
METHODS: We included 5,415 primary THAs from the DHR performed from July 1 to December 31, 2019. Version 3 of the DNPR was launched in February 2019, and a combination of data from the DNPR and a comprehensive national review of 1,762 hospital contacts enabled us to identify every dislocation occurring during the 1st year after THA to determine the "true" 1-year incidence of dislocation. The results were presented as proportions with 95% confidence intervals (CI), and validation was performed by calculating sensitivity and predictive values.
RESULTS: The "true" 1-year incidence of dislocation was 2.8% (CI 2.4-3.3). Of these, 37% suffered recurrent dislocations during the follow-up period. Between-hospital variation ranged from 0.0% to 9.6%. The algorithm demonstrated a sensitivity close to 95%, while maintaining a positive predictive value of above 94%.
CONCLUSION: The "true" 1-year incidence of dislocation of 2.8% is comparable to earlier findings, and large variation among hospitals continues to be evident. We have proven the algorithm to be valid in the latest DNPR (version 3), enabling it to be employed as a new quality indicator in future annual DHR reports.
Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 60 Weeks during the ITI Period. Participants who meet the criteria for ITI success will enter a tapering period of 16 weeks where the dose will be tapered down until a prophylactic dose, as judged by the Investigator, is achieved and thereafter a follow-up period of 32 weeks where the patient will continue to receive prophylactic treatment with rFVIIIFc.
Balance deficit represents one of the most frequent symptoms in patients with Multiple Sclerosis (PwMS) and one of the most disabling. Neuromotor rehabilitation is a fundamental tool for managing these symptoms: therapeutic exercise is currently the best choice for treating balance deficit. Once improvements has been achieved, this generally does not persist for a long time due to the underlying chronic-degenerative pathology: this reduction in clinical benefit, which can be graphically defined as a 'loss curve', is difficult to define due to individual differences, but it affects all MS patients. In recent years, new technologies are emerging, such as virtual reality and serious gaming, which are not presented as an alternative to intensive treatment but could find their ideal dimension in extensive treatment, allowing the patient to maintain the results achieved once the period of intensive treatment in a specialised rehabilitation facility is over. The specific objectives of this feasibility study are: to refine technical aspects of the Neuro Rehability system, to evaluate acceptability and satisfaction with its use by PwMS, to evaluate the recruitment process, adherence to the intervention, the number of drop-outs and identify potential problems, to evaluate the human resource requirements for the subsequent RCT study, to estimate the intervention effect and its variance necessary to calculate the appropriate sample size for the RCT.. Assessments will be carried out before the start (T0) and at the end (T1) of the treatment. The control group is asked to continue performing at home the normal physical activities that they may already be performing for the duration of the 12 weeks (TAU = treatment as usual). The experimental group is asked to perform the exercises of the Rehability platform, previously set up by the rehabilitation team on the basis of the training performed during the intensive rehabilitation period in the facility, at least 3 times a week and for at least 40 minutes per session. For both groups, no rehabilitation treatment will be possible except sphincter and phoniatric rehabilitation and psychological support. A descriptive statistical analysis will be used to describe the demographic and clinical characteristics of the sample. Standard data analysis techniques will be used to analyse the variables collected in both the feasibility study and the RCT. An electronic CRF will be set up to collect: clinical and demographic data on the recruited subjects; results of the tests/questionnaires.
The invention discloses a composite antibacterial agent, a preparation method and application thereof, and relates to the technical field of antibacterial agents. The antibacterial agent comprises chlorhexidine and cucurbituril [7] uril. In the antibacterial agent of the present invention, CHX is encapsulated in the cavity of CB [7] to form a 1:3 host-guest complex (CHX-3 CB [7 ]), and such a supramolecular complex exhibits higher antibacterial activity than CHX alone. UV-vis spectra show that the introduction of CB [7] promotes the protonation of the N atom on CHX, resulting in a stronger ionic interaction with phospholipids, thus enhancing the destruction of the bacterial membrane. Scanning Electron Microscopy (SEM), surface zeta potential and internal and external membrane integrity measurements also indicated that the incorporation of CB [7] increased membrane rupture. In addition, CHX has reduced cytotoxicity and irritation by forming a host-guest complex with CB.
Disclosed herein are methods for presenting therapy events on a continuous, time-based data feed. An algorithm for arranging data on the feed can position icons on the feed with information regarding therapy events at a time each event occurred without blocking or interfering with the data feed, including when the data feed is scrolled, zoomed, or otherwise repositioned. The algorithm can include clustering, buffering and affinity components. The clustering component can combine different events occurring at the same time into a single event and keep those events visually together on the data feed. The buffering component can provide a buffer around each event so there is no overlapping of depicted events. The affinity component provides an affinity for placing events as closed to a CGM trend line on the data feed as possible in view of the positioning of other events.
Lateral condylar humerus fractures are the second most common elbow fracture in children, accounting for approximately 17-20% of pediatric elbow fractures. Jakob et al. first described a novel classification based on the presence of cartilage bridging. It was modified by Foster et al. who identified the differences in outcomes between fractures with \< 2 mm and ≥ 2 mm displacement. most surgeons preferred open reduction and internal fixation (ORIF) to insure anatomic reduction of these unstable intra-articular fractures. Only a few reports have focused on closed reduction and Percutaneous Pinning (CRPP) of lateral condylar humeral fractures. In most studies, this technique was used only in cases with displacement between 2 and 4mm. CRPP has shown several advantages over ORIF, including less dissection of soft tissue around the fragment, low risk of vessel damage, low risk of non-union and avascular necrosis (AVN) of distal humerus physeal, shorter operating room times, and avoidance of an open incision with an unaesthetic scar. Song et al. introduced a new classification and an internal oblique view to better assess the displacement of the fragment, and they managed to achieve closed reduction of the fracture, even in cases with displacement exceeding 4mm or those with rotational displacement (graded as stage 5 according Song classification and Type III according to Jakob classification). Because the study was not controlled, we could not tell the difference between cases treated with CRPP and the cases treated with ORIF directly.

Since May 1, 2019, at our Institution, we have been treating type III lateral condyle fractures with CRPP. The primary objective of this study was to report the efficacy and safety of CRPP of lateral condyle fracture. The secondary aim was to compare the outcomes between CRPP and ORIF.